國立虎尾科技大學 |

Immunotherapy

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Immunotherapy/ edited by Aung Naing, Joud Hajjar.
其他作者:	Naing, Aung.
面頁冊數:	VIII, 182 p. 12 illus., 8 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Cancer research. -
電子資源:	https://doi.org/10.1007/978-3-030-02505-2
ISBN:	9783030025052

Immunotherapy
Immunotherapy[electronic resource] /edited by Aung Naing, Joud Hajjar. - 2nd ed. 2018. - VIII, 182 p. 12 illus., 8 illus. in color.online resource. - Advances in Experimental Medicine and Biology,9950065-2598 ;. - Advances in Experimental Medicine and Biology,889.

Overview of Basic Immunology and Translational Relevance for Clinical Investigators -- Immunotherapy for Melanoma -- Immunotherapy in Lung Cancer: A New Age in cancer treatment -- Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice -- Skin Reactions to Immune Checkpoint Inhibitors -- Immune-related Adverse Events: Pneumonitis -- Immune checkpoint inhibitors-induced colitis -- Immune checkpoint inhibitors-induced hepatitis -- Symptoms as patient-reported outcomes in cancer patients undergoing immunotherapies .

The second edition of Immunotherapy is an updated overview of immuno-oncology in acute myleloid leukemia, non-small cell lung cancer and melanoma, showcasing advances in the management of cancer broadly classified as hematological malignancies and solid tumors. Though the spectrum of clinical activity and duration of response seen with these agents is promising, objective response is limited to a subset of patients and is often associated with distinct side effects that are potentially life-threatening. With increasing use of checkpoint inhibitors as standard of care and in clinical trials, the burden of immune-related adverse events will undoubtedly increase. Given these limitations and increase in health care costs associated with such therapies, it is essential to identify patients who are likely to respond to immunotherapy and those who are at a risk for developing treatment-related side effects. This new edition will inform readers on the latest in biomarker development to identify patients who are more likely to respond, and strategies to overcome the challenges of immune-related adverse events. In addition, the authors recognize that including the missing patient voice in clinical trials and longitudinal assessment of symptom reports may help to identify early indicators of response or toxicity. Thus, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies. The authors believe that acquiring this knowledge will help health care professionals make informed treatment decisions. Edited by two renowned experts in the field, the book’s chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science.

ISBN: 9783030025052

Standard No.: 10.1007/978-3-030-02505-2doiSubjects--Topical Terms:

1253664
Cancer research.

LC Class. No.: RC261-271

Dewey Class. No.: 614.5999

Immunotherapy
LDR:03760nam a22004095i 4500 001 990253
003 DE-He213
005 20200704164446.0
007 cr nn 008mamaa
008 201225s2018 gw | s |||| 0|eng d
020 $a 9783030025052 $9 978-3-030-02505-2
024 7 $a 10.1007/978-3-030-02505-2 $2 doi
035 $a 978-3-030-02505-2
050 4 $a RC261-271
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 614.5999 $2 23
245 1 0 $a Immunotherapy $h [electronic resource] / $c edited by Aung Naing, Joud Hajjar.
250 $a 2nd ed. 2018.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a VIII, 182 p. 12 illus., 8 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Advances in Experimental Medicine and Biology, $x 0065-2598 ; $v 995
505 0 $a Overview of Basic Immunology and Translational Relevance for Clinical Investigators -- Immunotherapy for Melanoma -- Immunotherapy in Lung Cancer: A New Age in cancer treatment -- Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice -- Skin Reactions to Immune Checkpoint Inhibitors -- Immune-related Adverse Events: Pneumonitis -- Immune checkpoint inhibitors-induced colitis -- Immune checkpoint inhibitors-induced hepatitis -- Symptoms as patient-reported outcomes in cancer patients undergoing immunotherapies .
520 $a The second edition of Immunotherapy is an updated overview of immuno-oncology in acute myleloid leukemia, non-small cell lung cancer and melanoma, showcasing advances in the management of cancer broadly classified as hematological malignancies and solid tumors. Though the spectrum of clinical activity and duration of response seen with these agents is promising, objective response is limited to a subset of patients and is often associated with distinct side effects that are potentially life-threatening. With increasing use of checkpoint inhibitors as standard of care and in clinical trials, the burden of immune-related adverse events will undoubtedly increase. Given these limitations and increase in health care costs associated with such therapies, it is essential to identify patients who are likely to respond to immunotherapy and those who are at a risk for developing treatment-related side effects. This new edition will inform readers on the latest in biomarker development to identify patients who are more likely to respond, and strategies to overcome the challenges of immune-related adverse events. In addition, the authors recognize that including the missing patient voice in clinical trials and longitudinal assessment of symptom reports may help to identify early indicators of response or toxicity. Thus, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies. The authors believe that acquiring this knowledge will help health care professionals make informed treatment decisions. Edited by two renowned experts in the field, the book’s chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science.
650 0 $a Cancer research. $3 1253664
650 1 4 $a Cancer Research. $3 668358
700 1 $a Naing, Aung. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1139515
700 1 $a Hajjar, Joud. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1139516
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030025045
776 0 8 $i Printed edition: $z 9783030025069
776 0 8 $i Printed edition: $z 9783030378561
830 0 $a Advances in Experimental Medicine and Biology, $x 0065-2598 ; $v 889 $3 1253792
856 4 0 $u https://doi.org/10.1007/978-3-030-02505-2
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)